Suzhou Fushilai Pharmaceutical Co. Ltd. (301258) - Total Liabilities

Latest as of June 2025: CN¥211.52 Million CNY ≈ $30.95 Million USD

Based on the latest financial reports, Suzhou Fushilai Pharmaceutical Co. Ltd. (301258) has total liabilities worth CN¥211.52 Million CNY (≈ $30.95 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Suzhou Fushilai Pharmaceutical Co. Ltd. net asset momentum to track the company's year-over-year net asset growth rate.

Suzhou Fushilai Pharmaceutical Co. Ltd. - Total Liabilities Trend (2019–2024)

This chart illustrates how Suzhou Fushilai Pharmaceutical Co. Ltd.'s total liabilities have evolved over time, based on quarterly financial data. See Suzhou Fushilai Pharmaceutical Co. Ltd. free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Suzhou Fushilai Pharmaceutical Co. Ltd. Competitors by Total Liabilities

The table below lists competitors of Suzhou Fushilai Pharmaceutical Co. Ltd. ranked by their total liabilities.

Company	Country	Total Liabilities
Monarch Networth Capital Limited NSE:MONARCH	India	Rs3.17 Billion
Satrec Initiative Co. Ltd KQ:099320	Korea	₩136.20 Billion
StealthGas Inc NASDAQ:GASS	USA	$21.36 Million
Jiayuan Science and Technology Co.Ltd. SHE:301117	China	CN¥252.70 Million
Fujian Superpipe SHE:300198	China	CN¥1.57 Billion
Good Finance Securities Co Ltd TWO:6021	Taiwan	NT$22.81 Billion
Sonmez Pamuklu Sanayii AS IS:SNPAM	Turkey	TL795.58 Million
Eupraxia Pharmaceuticals Inc TO:EPRX	Canada	CA$5.43 Million

Liability Composition Analysis (2019–2024)

This chart breaks down Suzhou Fushilai Pharmaceutical Co. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 301258 stock market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	10.37	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.11	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.10	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Suzhou Fushilai Pharmaceutical Co. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Suzhou Fushilai Pharmaceutical Co. Ltd. (2019–2024)

The table below shows the annual total liabilities of Suzhou Fushilai Pharmaceutical Co. Ltd. from 2019 to 2024.

Year	Total Liabilities	Change
2024-12-31	CN¥200.84 Million ≈ $29.39 Million	+17.83%
2023-12-31	CN¥170.45 Million ≈ $24.94 Million	-19.50%
2022-12-31	CN¥211.75 Million ≈ $30.99 Million	-6.91%
2021-12-31	CN¥227.47 Million ≈ $33.29 Million	+37.35%
2020-12-31	CN¥165.61 Million ≈ $24.23 Million	-2.28%
2019-12-31	CN¥169.48 Million ≈ $24.80 Million	--

About Suzhou Fushilai Pharmaceutical Co. Ltd.

SHE:301258 China Biotechnology

Market Cap

$329.32 Million

CN¥2.25 Billion CNY

Market Cap Rank

#14267 Global

#4233 in China

Share Price

CN¥24.55

Change (1 day)

+5.32%

52-Week Range

CN¥21.91 - CN¥39.02

All Time High

CN¥63.49